Drug updated on 9/5/2024
Dosage Form | Injection (intravenous; up to 218 MBq/mL [5.89 mCi/mL]) |
Drug Class | Radioactive diagnostic agents |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
Latest News
Summary
- NETSPOT (gallium Ga 68 dotatate) is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
- This summary is based on the review of one systematic review/meta-analysis. [1]
- True Positivity Rates in Neuroendocrine Tumor Detection: ^64Cu-DOTATATE showed the highest true positivity rate at 82.4%, followed by ^68Ga-DOTATATE/TOC at 78.4%. These PET tracers outperformed the SPECT tracers, ^111In-DTPA-Octreotide (63.7%) and ^99mTc-EDDA/HYNIC-TOC (58.5%), indicating superior effectiveness in identifying neuroendocrine tumors.
- Comparison of PET vs. SPECT Tracers: The PET tracers (^64Cu-DOTATATE and ^68Ga-DOTATATE/TOC) demonstrated significantly higher true positivity rates compared to the SPECT tracers (^111In-DTPA-Octreotide and ^99mTc-EDDA/HYNIC-TOC), highlighting the enhanced accuracy of PET imaging in detecting neuroendocrine tumors.
- Population Considerations: The studies included both adult and pediatric patients with neuroendocrine tumors, but the studies did not specify differences in effectiveness among different population subgroups.
- Safety Information: There is no safety information available in the reviewed studies regarding the radiolabeled peptides (^111In-DTPA-Octreotide, ^99mTc-EDDA/HYNIC-TOC, ^68Ga-DOTATATE/TOC, ^64Cu-DOTATATE).
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
NETSPOT (gallium Ga 68 dotatate) Prescribing Information. | 2023 | Advanced Accelerator Applications USA, Inc., Millburn, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Head-to-head comparison between peptide-based radiopharmaceutical for PET and SPECT in the evaluation of neuroendocrine tumors: A systematic review. | 2022 | Current Issues in Molecular Biology |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
SNMMI procedure standard/EANM practice guideline for SSTR PET: Imaging neuroendocrine tumors. | 2023 | Journal of Nuclear Medicine |